These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23143830)

  • 21. Analyzing phase III studies in hospice/palliative care. a solution that sits between intention-to-treat and per protocol analyses: the palliative-modified ITT analysis.
    Currow DC; Plummer JL; Kutner JS; Samsa GP; Abernethy AP
    J Pain Symptom Manage; 2012 Oct; 44(4):595-603. PubMed ID: 22819439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study design for the evaluation of treatment.
    Morales AJ
    Semin Reprod Endocrinol; 1996 May; 14(2):111-8. PubMed ID: 8796933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Handling missing data in vaccine clinical trials for immunogenicity and safety evaluation.
    Li X; Wang WW; Liu GF; Chan IS
    J Biopharm Stat; 2011 Mar; 21(2):294-310. PubMed ID: 21391003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analyzing symptom management trials: the value of both intention-to-treat and per-protocol approaches.
    Given B; Given CW; Sikorskii A; You M; McCorkle R; Champion V
    Oncol Nurs Forum; 2009 Nov; 36(6):E293-302. PubMed ID: 19887342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of clinical trials for treatment of opiate dependence: what is missing?
    Jain RB
    NIDA Res Monogr; 1992; 128():29-36; discussion 37-45. PubMed ID: 1436014
    [No Abstract]   [Full Text] [Related]  

  • 26. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparisons between ITT and treatment emergent adverse event analyses.
    Quan H; Sun Q; Zhang J; Shih WJ
    Stat Med; 2008 Nov; 27(26):5356-76. PubMed ID: 18618431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intention-to-treat has implications for study planning and execution, not just subject retention and follow-up.
    Hodges JS
    J Clin Periodontol; 2008 Aug; 35(8):683-4. PubMed ID: 18727742
    [No Abstract]   [Full Text] [Related]  

  • 29. Quantified superiority of cognitive behaviour therapy to antidepressant drugs: a challenge to an earlier meta-analysis.
    Parker GB; Crawford J; Hadzi-Pavlovic D
    Acta Psychiatr Scand; 2008 Aug; 118(2):91-7. PubMed ID: 18452571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration guidance on progression-free survival and the intention-to-treat principle.
    Dixon D
    Clin Trials; 2015 Apr; 12(2):179. PubMed ID: 25644996
    [No Abstract]   [Full Text] [Related]  

  • 31. A probiotics trial on trial: the problem of timely detection of adverse advents in therapeutic trials.
    Giard RW
    J Clin Epidemiol; 2010 Apr; 63(4):347-9. PubMed ID: 19762211
    [No Abstract]   [Full Text] [Related]  

  • 32. Statistical analysis of clinical trials.
    Wassertheil-Smoller S; Kim MY
    Semin Nucl Med; 2010 Sep; 40(5):357-63. PubMed ID: 20674595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed.
    Hasford J; Bramlage P; Koch G; Lehmacher W; Einhäupl K; Rothwell PM
    J Clin Epidemiol; 2010 Dec; 63(12):1298-304. PubMed ID: 20172690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Missing data handling in chronic pain trials.
    Kim Y
    J Biopharm Stat; 2011 Mar; 21(2):311-25. PubMed ID: 21391004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intention to treat analysis: how frequently is it used in ENT randomised controlled trials?
    Achar P; Mitra I; Duvvi S; Kumar BN
    Clin Otolaryngol; 2010 Feb; 35(1):65-7. PubMed ID: 20447170
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessing causal relationships between treatments and clinical outcomes: always read the fine print.
    Freidlin B; Korn EL
    Bone Marrow Transplant; 2012 May; 47(5):626-32. PubMed ID: 21625225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [How one correctly handles protocol violations in complementary medicine].
    Lüdtke R
    Forsch Komplementmed; 2009 Dec; 16(6):368-9. PubMed ID: 20090349
    [No Abstract]   [Full Text] [Related]  

  • 38. [Evaluating treatment effect].
    Lindh J
    Lakartidningen; 2013 Jan 23-29; 110(4):159-62. PubMed ID: 23427725
    [No Abstract]   [Full Text] [Related]  

  • 39. Statistical issues in interpreting clinical trials.
    DeMets DL
    J Intern Med; 2004 May; 255(5):529-37. PubMed ID: 15078496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Intention-to-Treat Analysis Is Not Always the Conservative Approach.
    Shrier I; Verhagen E; Stovitz SD
    Am J Med; 2017 Jul; 130(7):867-871. PubMed ID: 28392186
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.